This renewal application focuses on studies to define the regulation of synthesis of the vitamin K dependent bone protein, osteocalcin by three factors which we believe are key to understanding its function. 1) the role of the pro-piece of osteocalcin in regulation of osteocalcin secretion, cleavage and Gla synthesis; 2) the precise function of Gla residue synthesis in osteocalcin and the requirements for vitamin K utilization in bone cells for Gla synthesis; and 3) specific definition of the induction of osteocalcin synthesis by calcitriol as related solely to cellular level of transcripts and/or to accelerated processing via the carboxylase enzyme and functionally to bone resorption. To achieve these objectives, specific questions of investigation are the following: a) the site (e.g., Golgi, microsomes, extracellular) of propiece cleavage and the mechanism (e.g., serine protease) of cleavage will be investigated; b) prove that the propiece is glycosylated and is a signal for secretion; c) define the effect of warfarin on the bone vitamin K cycle, intracellular precursor accumulation and osteocalcin peptide synthesis; d) determine the requirement of and precise number of Gla residues for pro- osteocalcin cleavage and osteocalcin function. The majority of the proposed studies will be carried our in a newly developed chick osteoblast culture system in which second passage cells (greater than 90% pure osteoblasts) undergo a programmed differentiation throughout a 3 week culture period producing a matrix that calcifies even in the absence of a chemical inductant. In this system pro-osteocalcin and osteocalcin function can be addressed by examining alterations in matrix formation, mineral deposition and bone cell activity (measuring parameters of alkaline phosphatase and collagen synthesis) that result from 1) inhibition of propeptide cleavage; 2) inhibition of pro-osteocalcin secretion; 3) inhibition of Gla synthesis in the protein by warfarin; and 4) the induction of osteocalcin synthesis by calcitriol. Utilizing a cDNA probe of osteocalcin, mRNA levels and activity will be quantitated as affected by warfarin and calcitriol and how inhibition of these regulative factors effect bone cell activity and calcified matrix formation, will allow us to better define its function and thereby provide a more meaningful parameter of osteocalcin measurements in a clinical setting.

Agency
National Institute of Health (NIH)
Institute
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Type
Research Project (R01)
Project #
5R01AR033920-08
Application #
3156680
Study Section
Orthopedics and Musculoskeletal Study Section (ORTH)
Project Start
1989-04-01
Project End
1992-03-31
Budget Start
1991-04-01
Budget End
1992-03-31
Support Year
8
Fiscal Year
1991
Total Cost
Indirect Cost
Name
University of Massachusetts Medical School Worcester
Department
Type
Schools of Medicine
DUNS #
660735098
City
Worcester
State
MA
Country
United States
Zip Code
01655
Hoffmann, H; Green, J; van Wijnen, A J et al. (2000) Expression screening of factors binding to the osteocalcin bone-specific promoter element OC box I: isolation of a novel osteoblast differentiation-specific factor. J Cell Biochem 80:156-68
Banerjee, C; McCabe, L R; Choi, J Y et al. (1997) Runt homology domain proteins in osteoblast differentiation: AML3/CBFA1 is a major component of a bone-specific complex. J Cell Biochem 66:1-8
Frenkel, B; Capparelli, C; Van Auken, M et al. (1997) Activity of the osteocalcin promoter in skeletal sites of transgenic mice and during osteoblast differentiation in bone marrow-derived stromal cell cultures: effects of age and sex. Endocrinology 138:2109-16
Lian, J B; Shalhoub, V; Aslam, F et al. (1997) Species-specific glucocorticoid and 1,25-dihydroxyvitamin D responsiveness in mouse MC3T3-E1 osteoblasts: dexamethasone inhibits osteoblast differentiation and vitamin D down-regulates osteocalcin gene expression. Endocrinology 138:2117-27
Ryoo, H M; Hoffmann, H M; Beumer, T et al. (1997) Stage-specific expression of Dlx-5 during osteoblast differentiation: involvement in regulation of osteocalcin gene expression. Mol Endocrinol 11:1681-94
Lian, J B; Stein, G S; Stein, J L et al. (1996) The osteocalcin gene promoter provides a molecular blueprint for regulatory mechanisms controlling bone tissue formation: role of transcription factors involved in development. Connect Tissue Res 35:15-21
Staal, A; van Wijnen, A J; Birkenhager, J C et al. (1996) Distinct conformations of vitamin D receptor/retinoid X receptor-alpha heterodimers are specified by dinucleotide differences in the vitamin D-responsive elements of the osteocalcin and osteopontin genes. Mol Endocrinol 10:1444-56
Hoffmann, H M; Beumer, T L; Rahman, S et al. (1996) Bone tissue-specific transcription of the osteocalcin gene: role of an activator osteoblast-specific complex and suppressor hox proteins that bind the OC box. J Cell Biochem 61:310-24
Banerjee, C; Hiebert, S W; Stein, J L et al. (1996) An AML-1 consensus sequence binds an osteoblast-specific complex and transcriptionally activates the osteocalcin gene. Proc Natl Acad Sci U S A 93:4968-73
Banerjee, C; Stein, J L; Van Wijnen, A J et al. (1996) Transforming growth factor-beta 1 responsiveness of the rat osteocalcin gene is mediated by an activator protein-1 binding site. Endocrinology 137:1991-2000

Showing the most recent 10 out of 82 publications